|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
FY2023
12 months to Dec 31, 2023
|
FY2022
12 months to Dec 31, 2022
|
FY2012
12 months to Dec 31, 2012
|
|
|---|---|---|---|---|---|
| Revenues | |||||
| Cost of revenues | |||||
| Gross profit | |||||
| Administrative fee income | |||||
| Operating expenses: | |||||
| Research and development expenses | |||||
| Research and development expenses, net | |||||
| General and administrative expenses | |||||
| NewStem Ltd | |||||
| Total general and administrative expenses | |||||
| Contra expenses - legal fees | |||||
| Litigation expenses (Note 7) | |||||
| Total operating expenses | |||||
| Loss from operations | |||||
| NewStem Ltd | |||||
| Total loss from operations | |||||
| Other (income) expenses: | |||||
| Loss on derivative instrument | |||||
| Impairment loss on equity method investee | |||||
| Gain on disposal of equity method investment | |||||
| Relief of indebtedness income | |||||
| Interest expense | |||||
| Total other (income) expenses | |||||
| Financial income, net | |||||
| Income (loss) before income taxes | |||||
| NewStem Ltd | |||||
| Total income (loss) before income taxes | |||||
| Net loss before equity in net loss of equity method investees | |||||
| Net income (loss) before equity in net loss of equity method investees | |||||
| Equity in net income (loss) of equity method investees | |||||
| Gain on dilution of equity method investment | |||||
| Income from (impairment of) equity method investee, NewStem | |||||
| Net income (loss) | |||||
| NewStem Ltd | |||||
| Total net income (loss) | |||||
| Basic and diluted net income (loss) per share: | |||||
| Net income (loss) per share - basic | |||||
| Weighted average number of shares outstanding – basic | |||||
| Net income (loss) per share - diluted | |||||
| Weighted average number of shares outstanding - diluted | |||||
Loading...